Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc. > AGN receives US patent for CKD drug
View:
Post by XeniaTechie on Apr 21, 2023 11:37am

AGN receives US patent for CKD drug

Algernon Pharmaceuticals Inc.has received a Notice of Allowance from the United States Patent and Trademark Office for its lead drug NP-251 (Repirinast), a promising candidate for treating chronic kidney disease and non-alcoholic fatty liver disease. Repirinast was previously marketed by Mitsubishi Tanabe Pharma to treat asthma, and Algernon has since obtained a supply from a Chinese manufacturer. Preclinical studies have shown Repirinast to reduce hepatic fibrosis by 57% and the NAFLD score by 31%, making it a strong candidate for treatment. Algernon's patent applications protect their intellectual property strategy. https://financialpost.com/globe-newswire/algernon-pharmaceuticals-announces-notice-of-allowance-for-method-of-use-u-s-patent-application
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities